GL Pharm Tech Corp. (KOSDAQ: 204840)

Market Cap	75.35B
Revenue (ttm)	24.90B
Net Income (ttm)	-3.42B
Shares Out	76.97M
EPS (ttm)	-48.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,972
Average Volume	95,416
Open	976.00
Previous Close	988.00
Day's Range	970.00 - 998.00
52-Week Range	944.00 - 1,540.00
Beta	1.09
RSI	46.76
Earnings Date	Mar 14, 2025

About GL Pharm Tech

GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease. Further...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 27
• Stock Exchange: KOSDAQ
• Ticker Symbol: 204840

Financial Performance

In 2023, GL Pharm Tech's revenue was 26.03 billion, an increase of 55.62% compared to the previous year's 16.73 billion. Losses were -3.75 billion, 374.4% more than in 2022.